bluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

bluebird bio, Inc. (NASDAQ:BLUE) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $10.29 and traded as low as $6.20. bluebird bio shares last traded at $7.25, with a volume of 286,502 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Barclays upped their price objective on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Finally, StockNews.com initiated coverage on bluebird bio in a research report on Friday, December 20th. They issued a “sell” rating on the stock. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, bluebird bio currently has a consensus rating of “Hold” and an average price target of $49.14.

bluebird bio Stock Up 13.5 %

The business has a 50 day simple moving average of $8.00 and a 200 day simple moving average of $10.29. The company has a market capitalization of $70.47 million, a price-to-earnings ratio of -0.19 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

Institutional Trading of bluebird bio

A number of institutional investors and hedge funds have recently bought and sold shares of BLUE. SG Americas Securities LLC increased its position in shares of bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 74,185 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new stake in bluebird bio during the 4th quarter worth about $175,000. Barclays PLC increased its holdings in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the period. Geode Capital Management LLC raised its position in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares during the period. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.